Tag: CASI Pharmaceuticals
CASI Pharmaceuticals administers first FOLOTYN dose in China for PTCL treatment
In a significant stride toward addressing the critical medical needs of peripheral T-cell lymphoma (PTCL) patients in China, CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a trailblazer ... Read More